A six-sheet KOL universe and engagement workbook, built gate by gate: sizing, tier classification, scientific influence, engagement readiness, MSL territory coverage, and cross-border network. Every KOL entry carries a verification tag.
A single five-centre South West England consortium tracks 666 UK patients across all three approved CDK4/6 inhibitors. That kind of coordinated, multi-centre evidence generation is exactly the institutional signal this workbook sizes before any individual name enters it.
Six NHS centres, Great Ormond Street, Bristol, Alder Hey, Birmingham Children's, Leeds, and Newcastle, concentrate the UK's refractory Dravet syndrome cohort, and the British Paediatric Neurology Association's Dravet working group shapes NICE evidence review 18-24 months ahead of submission. That institutional network is what this workbook sizes first, not a roster of named physicians.
Five NHS specialist centres, Sheffield, Cambridge, Birmingham, Guy's and St Thomas', and Manchester, manage more than 90% of UK HAE patients. That concentration is what this workbook sizes before any physician enters the K1-K6 gate structure.
KFSH&RC, AUH, and Hamad Medical Corporation anchor a GCC HAE specialist community that SACIA sizes at just 6-10 physicians regionwide. That concentration is exactly what this workbook sizes before any individual name enters it.
Five named NHS lysosomal storage disorder centres, and Royal Free London's National Fabry Service, named NICE's appointed clinical expert for both migalastat's HST4 and pegunigalsidase alfa's TA915. That repeated appointment is exactly the institutional signal this workbook sizes before any individual name enters it.
The National Amyloidosis Centre holds the clinical-expert seat at every NICE ATTR appraisal to date. This workbook sizes the UK ATTR KOL network before a name enters it: NAC's 400-500-patient ATTRv surveillance registry, the separate UCL and Queen Elizabeth Hospital Birmingham National ATTRv Registry tracking approximately 800 patients, and the roughly 30 NHS centres running Tc-PYP scintigraphy nationally.
KFSH&RC runs the only HEK293 amenable-mutation assay in the GCC, and its formulary committee recommendation drives NPHC coverage decisions for every Fabry disease treatment. That kind of single-institution gatekeeping is exactly the concentration this workbook sizes before any individual name enters it.
The Renal Association's IgAN guideline committee, not any single physician, sets the clinical reference point NICE checks technology appraisals against. This workbook sizes that committee and the network behind it before individual outreach begins.
A 30-centre NHS neuromuscular network coordinated through Muscular Dystrophy UK, plus a 3,000-member Myasthenia Gravis Association UK patient registry, is the institutional signal this workbook sizes before any individual name enters it.
KFSH&RC maintains the only GCC-wide ATTRv genetic registry and houses the region's nuclear cardiology programme. Fewer than 8 named cardiology and scintigraphy centres region-wide, spanning KAMC, AUH, HMC Doha, and OCCI Muscat, define a small institutional field this workbook sizes before any individual name enters it.
GCC IgA nephropathy expertise concentrates in five named tertiary centres and roughly 300 practicing nephrologists, of whom 30 to 50 carry glomerular-disease subspecialty interest. This workbook sizes that concentrated institutional base before any individual name enters it.
Four London teaching hospitals, Barts, King's, Imperial, and Homerton, anchor roughly 6,000 of the UK's 15,000-17,000 sickle cell patients, with Birmingham Heartlands, Manchester, Bristol, and Nottingham forming the next concentration ring. That eight-centre structure is exactly the institutional signal this workbook sizes before any individual name enters it.
Just 8-10 to 10-15 neuromuscular neurologists across six named GCC referral centres manage 70-80% of confirmed generalised myasthenia gravis. That concentration is exactly what this workbook sizes before any individual name enters it.
A five-centre UK Pompe Consortium and an eight-centre NHS Highly Specialised Service network concentrate expertise around a six-physician BIMDG subcommittee that advises NICE directly. That kind of institutional concentration is exactly what this workbook sizes before any individual name enters it.
Four NHS Highly Specialised Services networks and six designated gene-therapy centres carry the UK SMA treatment pathway. This workbook sizes that institutional structure, plus the Bristol Institute of Child Health attenuation-cohort follow-up, before any physician name enters it.
KFSH&RC, KAMC, and AUH are the only GCC institutions running structured adult sickle cell disease programmes across a population of 200,000-250,000 patients. That three-centre concentration, anchored by the KFSH&RC Dammam flagship and 12+ MOH regional centres in Eastern Province, is exactly the institutional signal this workbook sizes before any individual name enters it.
Four designated GCC centres, KAMC, KFSH&RC in Riyadh, Sidra Medicine in Doha, and SKMC in Abu Dhabi, carry nearly all regional SMA gene-therapy and specialist referral activity. This workbook sizes that institutional concentration before any individual name enters it.
Six to eight named metabolic centres across the GCC hold enzyme replacement therapy infusion capacity for Pompe disease, led by KFSH&RC's roughly 120-patient, 15-year treatment experience. That kind of institutional concentration is exactly what this workbook sizes before any individual name enters it.
Seven institutions across Riyadh, Jeddah, Dubai, and Abu Dhabi concentrate the GCC's confirmed PNH caseload, and just 5 to 8 physicians function as genuine adoption gatekeepers. That kind of concentration is exactly what this workbook sizes before any individual name enters it.
Five NHS Highly Specialised Services centres, anchored by the Leeds National PNH Service, concentrate fewer than 25 consultants managing over 90% of the UK's PNH caseload. That kind of institutional concentration is exactly the signal this workbook sizes before any individual name enters it.
Saint-Louis Hospital anchors France's MaRIH-coordinated PNH reference network of 14 competence centres, but only 24 of the 50-plus centres in the national clone-observatory network actively report into it. That kind of institutional structure is exactly what this workbook sizes before any individual name enters it.
A 9,146-patient US real-world study found no significant survival difference between palbociclib, ribociclib, and abemaciclib. When the drugs perform equivalently, KOL guidance decides which one gets prescribed, not clinical data.
A five-institution Saudi pediatric neurology consortium spanning Riyadh, Jeddah, and Dammam tracked 44 Dravet syndrome patients on stiripentol combination therapy. That kind of coordinated, cross-city publication is exactly the institutional signal this workbook sizes before any individual name enters it.
An editable 6-sheet Excel KOL workbook (Universe, Tier Scoring, Engagement Calendar, MSL Territory, Cross-Border Network, Evidence Register), a PDF summary brief, and a 45-minute analyst call.
Every KOL entry is built from live PubMed, ClinicalTrials.gov, and guideline-authorship data, then tagged Verified / Industry benchmark / Requires client validation — no name ships unverified.
Yes. You set the indication, geography, and institution scope; the workbook is built to your scope and delivered editable.